Frentizole - CAS 26130-02-9
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Frentizole, a nontoxic antiviral and immunosuppressive agent used clinically in rheumatoid arthritis and systemic lupus erythematosus, displayed a slightly improved activity (IC50 = 200 lM) compared to thioflavine T(IC50 = 230 lM).
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
An FDA-approved immunosuppressive drug, a novel inhibitor of the Aβ–ABAD interaction (IC50 = 200 lM)
Solid powder
1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea; 7EY946394I; frentizole; mono-hydrate of frentizole; FRENTIZOLE; 26130-02-9; Frentizol; Compound 53616; MLS000555007; CHEMBL128988; UNII-7EY946394I; 1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea; NCGC00160657-01; SMR000147124; 1-(6-Methoxy-benzothiazol-2-yl)-3-phenyl-urea; DSSTox_CID_26279; DSSTox_RID_81505; 1-(6-methoxybenzo[d]thiazol-2-yl)-3-phenylurea; DSSTox_GSID_46279; CAS-26130-02-9; Frentizolum; Frenazole; AC1Q4EVH; Frentizole (USAN/INN); Opera_ID_1653; Frentizol [INN-Spanish]; Frentizolum [INN-Latin]; AC1L1PF2; Oprea1_516941; cid_33334; MLS001201824; Bio-0413; Frentizole [USAN:INN:BAN]; SCHEMBL599582; DTXSID5046279; HMS2233G12; HMS3370C02; ZINC8994439; Tox21_111964; 3684AH; BDBM50189352; STK078558; ZINC08994439; AKOS001049350; Tox21_111964_1; 7EY946394I; CS-0841; MCULE-7561551977; NCGC00160657-03; AK468739; DR001179; HE329695; HY-15374; LY 53616; ST50103599; 1-(6-Methoxy-2-benzothiazolyl)-3-phenylurea; 1-(6-methoxybenzothiazol-2-yl)-3-phenylurea; D00159; W-5046; Urea, N-(6-methoxy-2-benzothiazolyl)-N'-phenyl-; 3-(6-methoxy-1,3-benzothiazol-2-yl)-1-phenylurea; N-(6-methoxybenzothiazol-2-yl)(phenylamino)carboxamide; T0510-0233
DMSO: ≥ 3 mg/mL
Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -22℃ for long term (months to years).
Anti-Alzheimer agents; Amyloid-β inhibitor
Canonical SMILES:
1.Comparative effects of azathioprine, cyclophosphamide and frentizole on cellular immunity in mice.
Smith SR, Terminelli C, Kipilman CT, Smith Y. J Immunopharmacol. 1981;3(2):133-70.
This report extends previous observations on the immunosuppressive properties of cyclophosphamide (CPA), azathioprine and frentizole (15) to include murine models of cellular immunity. Systemic and local graft vs host reactions (GVHR) were most effectively suppressed by CPA. In contrast to frentizole, both CPA and azathioprine were found to inhibit the proliferation of parental T-cells in a systemic GVHR. However, CPA was the only agent capable of inhibiting the proliferation of T-cells following contact sensitization with oxazolone. Mice pretreated with a high dose of CPA or frentizole prior to inoculation with the murine sarcoma virus exhibited accelerated tumor growth. However, there was no accelerated growth of murine sarcoma virus induced tumors or an SaI spindle cell fibrosarcoma during rather prolonged therapy with immunosuppressive doses of CPA, azathioprine or frentizole. Normal mice treated with CPA showed a more drastic reduction in lymphoid elements of the spleen and thymus than mice treated with azathioprine or frentizole.
2.Frentizole therapy in systemic lupus erythematosus.
Sabharwal UK, Vaughan JH, Kaplan RA, Robinson CA, Curd JG. Arthritis Rheum. 1980 Dec;23(12):1376-80.
Seven corticosteroid dependent patients with active systemic lupus erythematosus (SLE) were given frentizole in order to assess its effect on their clinical manifestations. Three patients exhibited slight clinical improvement, 2 patients did not change, and 2 deteriorated. Five of the 7 patients developed subclinical and reversible liver damage related to frentizole. This study, although preliminary and uncontrolled, suggests that frentizole is of limited value in the management of patients with SLE.
3.The immunomodulatory action of frentizole, a novel immunosuppressive agent.
Hatfield SM, Hartley LW, Schmidtke JR. Immunopharmacology. 1982 Dec;5(2):169-79.
The in vitro effects of frentizole and methylprednisolone on human PBL were examined. Both drugs exhibited differential effects on lymphocyte subpopulations. Frentizole was more effective in suppressing human lymphocytes responding to Con A and PWM, than it was in cells activated by PHA, specific antigen, or alloantigen. Methylprednisolone, on the other hand, was more inhibitory for cells stimulated by PHA, specific antigen, or alloantigen. These data suggest that frentizole has a preferential effect on the cytotoxic/suppressor subpopulation of human T lymphocytes while methylprednisolone appears to preferentially affect the helper/inducer subset. Differences in potency between the two drugs were also observed. Methylprednisolone was better able to maintain its inhibitory effects during longer periods of culture than frentizole. Both agents were less effective if their addition to the culture was delayed 24-48 hrs and neither drug was very effective in overcoming the adjuvant action of poly A:U on mitogenically activated human PBL.
4.Frentizole therapy of thrombocytopenia in systemic lupus erythematosus and refractory idiopathic thrombocytopenic purpura.
O'Duffy JD, Colgan JP, Phyliky RL, Ferguson RH. Mayo Clin Proc. 1980 Oct;55(10):601-5.
Frentizole, an immunosuppressive phenylurea agent, used in a dosage of 4 mg/kg per day, was found to produce quick elevation of platelet counts in three thrombocytopenic patients. Two have systemic lupus erythematosus, and one has resistant idiopathic thrombocytopenic purpura. Corticosteroid dosage could be reduced in all three patients, and thus far platelet counts are being maintained at "safe" levels. Although major toxicity has limited the utility of frentizole, its effect on the platelet counts of these thrombocytopenic patients is of interest.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Amyloid-β Products

Y-29794 Tosylate
(CAS: 146794-84-5)

Y-29794 Tosylate, a novel orally non-peptide PPCE inhibitor, has shown to be able to prevent amyloid-like deposition in senescence-accelerated mice.Y-29794 exhi...

CAS 145915-58-8 CGP 52411

CGP 52411
(CAS: 145915-58-8)

CGP 52411, also called DAPH, inhibits and reverses the formation of Aβ42 fibers (β-sheet content of aggregated β-amyloid (1-42): IC50 = 4.5 µM) in neurons assoc...

CAS 26130-02-9 Frentizole

(CAS: 26130-02-9)

Frentizole, a nontoxic antiviral and immunosuppressive agent used clinically in rheumatoid arthritis and systemic lupus erythematosus, displayed a slightly impr...

CAS 145915-60-2 CGP 53353

CGP 53353
(CAS: 145915-60-2)

CGP 53353, also called DAPH 2, highly selectively inhibits procarcinogenic protein kinase C-βII (PKCβII) ,and it is also an inhibitor of prionogenic Sup35 fibr...

CAS 208255-80-5 DAPT

(CAS: 208255-80-5)

DAPT, also called γ-Secretase Inhibitor IX, is a potent and selective inhibitor of γ-secretase which leads to a reduction in Aβ40 and Aβ42 levels in human prima...

CAS 290315-45-6 BMS 299897

BMS 299897
(CAS: 290315-45-6)

BMS 299897, under the IUPAC name 4-[2-[(1R)-1-(N-(4-chlorophenyl)sulfonyl-2,5-difluoroanilino)ethyl]-5-fluorophenyl]butanoic acid, synthesized by the radiosynth...

CAS 293762-45-5 Ro 90-7501

Ro 90-7501
(CAS: 293762-45-5)

Ro 90-7501, under the IUPCAS name 2-[2-(4-aminophenyl)-3H-benzimidazol-5-yl]-3H-benzimidazol-5-amine, a type of aminoquinolines, is an inhibitor of Aβ42 fibril ...

(CAS: 700361-48-4)

LPYFD-NH2, is a neuroprotective peptide that binds to Amyloid-β. In vitro and in vivo it protects neurons against toxic effects of Aβ (1-42), which can be used ...

Amyloid β-peptide (42-1) (human)
(CAS: 317366-82-8)

Amyloid β-peptide (42-1) (human), is the predominant form of amyloid β-peptide found in the brains of patients with Alzheimer's disease.

(CAS: 945714-67-0)

FPS-ZM1 is a high-affinity RAGE-specific blocker that inhibits amyloid-β binding to the V domain of RAGE with Ki of 25 ± 5 nM in RAGE-transfected CHO cells. It ...

CAS 53902-12-8 Tranilast

(CAS: 53902-12-8)

Tranilast, also called Rizaben or Tranilastum, has anti-inflammatory and immunomodulatory effect. It binds to Aβ40 monomers and increases Aβ40 fibrillation.

CAS 937812-80-1 gamma-Secretase modulators

gamma-Secretase modulators
(CAS: 937812-80-1)

gamma-Secretase Modulators, as a potent modulator of γ-secretase, it is derived from oxadiazine. IC50: Aβ42=11 nM, Aβtotal/ Aβ42=1170.

AC 186
(CAS: 1421854-16-1)

AC 186, also called GTPL8897, a diphenyl substituted cyclohexane derivatives, decreases Aβ levels in combination with ACP-105 in a rat model of Alzheimer's dise...

CAS 313967-18-9 FLI-06

(CAS: 313967-18-9)

FLI-06 , a Notch inhibitor that disrupts Notch trafficking and processing, disrupts the Golgi by mechanisms different from BFA or GCA. It Reduces amyloid β secr...

CAS 989-51-5 EGCG

(CAS: 989-51-5)

EGCG, also called Epigallocatechin gallate, under the IUPAC name [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxy...

CAS 568-72-9 Tanshinone IIA

Tanshinone IIA
(CAS: 568-72-9)

Tanshinone IIA, under the IUPAC name 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g][1]benzofuran-10,11-dione, one of the original anthracyclines isolated from Sa...

CAS 956128-01-1 SEN 1269

SEN 1269
(CAS: 956128-01-1)

SEN 1269, under the IUPAC name 3-[[5-[3-(dimethylamino)phenoxy]pyrimidin-2-yl]amino]phenol, is a derivative of pyrimidine that inhibits Amyloid-β (Aβ) aggregati...

CAS 867021-83-8 Colivelin

(CAS: 867021-83-8)

Colivelin, as a neuroprotective peptide and activator of STAT3 it is able to suppresses neuronal death. It is also able to protect neurons against the neurotoxi...

CAS 173550-33-9 Compound W

Compound W
(CAS: 173550-33-9)

Compound W, also called 3,5-bis(4-Nitrophenoxy)benzoic acid, a 3,3'-diiodothyronine sulfate cross-reactive substance, is an inhibitor of γ-secretase which cause...

(CAS: 863918-78-9)

Methoxy-X04, also called CHEMBL2181036, as a Fluorescent Amyloid-β (Aβ) probe, can be easily synthesized with carbon-11 (11C), it can detect and quantify plaque...

Chemical Structure

CAS 26130-02-9 Frentizole

Quick Inquiry

Verification code

Featured Items